

million-women translating to tens-of-thousands more breast/ovarian-cancers prevented across the population.

Conclusions Population-based BRCA-testing is cost-effective in HIC and potentially in UMIC depending on the local willingness-to-pay thresholds. Genetic-testing costs need to fall further for LMIC cost-effectiveness. Population-testing can prevent tens-of-thousands more breast/ovarian-cancers than the current clinical strategy.

IGCS19-0579

11 FLABRA, FRONTLINE APPROACH FOR BRCA TESTING IN OVARIAN CANCER (OC) TREATMENT NAÏVE POPULATION. A LATIN AMERICA (LA) EPIDEMIOLOGIC STUDY

¹S Goncalves, ²G Gomez Abuin, ³D Gallardo, ⁴P Estevez Diz, ⁵V Caceres, ⁶M De la Vega, ⁷F Palazzo, ⁸G Lerzo, ⁹D Kaen, ¹⁰R Gerson, ¹¹M Lim, ¹²M Philco, ¹³M Moreira Costa Zorzeto, ¹⁴AC De Melo, ¹⁵R Hegg, ¹⁶R de Oliveira Santana, ¹⁷P Medeiros Milhomen Beato, ¹⁸L Trujillo, ¹⁹M Plata, ²⁰A Yepes, ²¹A Cock, ²²MM Bonifacino, ²³M Cortes, ²⁴L Fein, ²⁵C Castillo, ²⁶C Pacheco, ²⁷M Ticona, ²⁸E Hoyosa, ²⁹R Jaramillo, ³⁰J Soare Nunes, ³¹A Menezes Morelle, ³²A Freire de Carvalho Calabrich, ³³EH Cronemberger Costa e Silva, ³⁴P Mora, ³⁵F Damian, ³⁶I Diaz Perez, ³⁷L Sganga, ³⁸MH Pereira, ³⁹H Ramirez, ⁴⁰A Nogueira, ⁴¹R Guindalini, ⁴²V Miranda, ⁴³G Giornelli*. ¹ASTRAZENCA, Medical Affairs LATAM, Buenos Aires, Argentina; ²Hospital Aleman, Oncology, Buenos Aires, Argentina; ³INCAN, Oncology, Mexico, Mexico; ⁴Instituto do Câncer do Estado de São Paulo – ICESP, Oncology, San Paulo, Brazil; ⁵Instituto Angel Roffo, Oncology, Buenos Aires, Argentina; ⁶CEMIC, Oncology, Buenos Aires, Argentina; ⁷Instituto Sagrada Familia, Oncology, San Miguel de Tucuman, Argentina; ⁸Instituto Fundación Investigar, Oncology, Buenos Aires, Argentina; ⁹COIR, Oncology, La Rioja, Argentina; ¹⁰The American British Cowdray Medical Center I.A.P. Centro Medico ABC, Oncology, Mexico, Mexico; ¹¹Instituto Oncológico Nacional, Oncology, Panama, Panama; ¹²Hospital Nacional Alberto Sabogal Sologuren, Oncology, Callao, Peru; ¹³Hospital do Câncer de Barretos, Oncology, San Paulo, Brazil; ¹⁴Instituto Nacional de Câncer INCA, Oncology, Rio de Janeiro, Brazil; ¹⁵Hospital Pérola Byington, Oncology, Sao Paulo, Brazil; ¹⁶Instituto do Câncer do Ceará, Oncology, Ceara, Brazil; ¹⁷Fundação Amaral Carvalho, Oncology, Sao Paulo, Brazil; ¹⁸Instituto Nacional de Cancerología, Oncology, Bogota, Colombia; ¹⁹Fundación Cardio Infantil, Oncology, Bogota, Colombia; ²⁰Clinica Vida, Oncology, Medellin, Colombia; ²¹Instituto de Cancerología de la Clínica las Américas, Oncology, Medellin, Colombia; ²²Nuvisan, Latinamerica, Buenos Aires, Argentina; ²³Instituto Reina Fabiola, Oncology, Cordoba, Argentina; ²⁴Centro Oncológico de Rosario, Oncology, Rosario, Argentina; ²⁵Hospital Perrando, Oncology, Resistencia, Argentina; ²⁶ONCOSALUD, Oncology, Lima, Peru; ²⁷Hosp. Edgardo Rebagliati, Oncology, Lima, Peru; ²⁸Oncomédica – IMAT, Oncology, Monteria, Colombia; ²⁹Hemato Oncólogos Cali, Oncology, Cali, Colombia; ³⁰Hospital Erasto Gaertner, Oncology, Curitiba, Brazil; ³¹Hospital Moinhos de Vento, Oncology, Sao Paulo, Brazil; ³²Ensino e terapia de Inovação Clínica AMO, Oncology, Rio Vermelho, Brazil; ³³Centro Regional Integrado de Oncología – CRIO, Oncology, Alvaro Weyne, Brazil; ³⁴Instituto COI de Pesquisa, Oncology, Rio de Janeiro, Brazil; ³⁵Pontificia Universidade Católica do Rio Grande do Sul, oncology, Rio Grande do Sul, Brazil; ³⁶AstraZeneca, Medical Affairs, Buenos Aires, Argentina; ³⁷AstraZeneca, Diagnostics, Buenos Aires, Argentina; ³⁸AstraZeneca, Medical LATAM, Sao Paulo, Brazil; ³⁹Fundacion Valle de Lili, Oncology, Valle de Lili, Colombia; ⁴⁰Angelica Nogueira Hospital das Clínicas- UFMG, Oncology, Sao Paulo, Brazil; ⁴¹CLION Salvador, Oncology, Salvador, Brazil; ⁴²Vanessa Miranda Instituto D'OR, Oncology, Sao Paulo, Brazil; ⁴³Instituto Alexander Fleming, Oncology, Buenos Aires, Argentina

10.1136/ijgc-2019-IGCS.11

Objectives Previously described prevalence of BRCA mutated OC is 14% for germline BRCA mutations (gBRCA^M), that could increase to 20% considering somatic BRCA mutations (sBRCA^M). Latinamerican population is a paradigm of poly-ethnicity and ancestries and the prevalence of BRCA^M is unknown.

FLABRA is a cross-sectional, multi-center study designed to determine the prevalence of BRCA^M, either sBRCA^M or gBRCA^M in high grade serous OC LA patients, with a new approach of start testing in tumor. We also aimed to describe current genetic counselling and treatment approach at frontline in this population.

Methods We enrolled 407 patients from Argentina, Brazil, Colombia, Mexico, Peru and Panama, diagnosed with OC within the last 120 days. Archived tumor blocks or 10- μ m sections were used for BRCA testing in tissue (Myriad Tumor BRCAAnalysis CDxTM). Patients who were positive in tumor, were analysed in blood to determine if the mutation was from germline (Myriad Single Site BRCAAnalysis[®]). In gBRCA^M, genetic counseling was advised. Patients medical records were reviewed for data relevant to medical history, OC diagnosis, counseling approach, and treatment plan.

Results Results from first 376 patients who already completed the study: BRCA mutations prevalence detected in tumor was 30%.

Conclusions Our data show a high prevalence of sBRCA^M and gBRCA^M in LA OC pts. Additionally, this new approach of start testing the tumor may prove to be more cost effective, leading to a more conclusive result; so refinement of this technique is a must. The high prevalence of sBRCA^M in certain regions of LA needs to be further investigated.

IGCS19-0443

12 GENETIC ANALYSIS OF PRIMARY AND RECURRENT ADULT GRANULOSA CELL TUMORS OF THE OVARY

¹A Da Cruz Paula*, ²E da Silva, ³S Segura, ⁴R Bi, ⁵P Selenica, ⁶F Pareja, ^{3A} Vidal, ^{4S} Gatius, ^{1NR} Abu-Rustum, ^{3X} Matias-Guiu, ^{3BP} Rubin, ^{2J} Reis-Filho, ^{2DF} DeLair, ^{2B} Weigelt. ¹Memorial Sloan Kettering Cancer center, Surgery, New York, USA; ²Memorial Sloan Kettering Cancer center, Pathology, New York, USA; ³Hospital U de Bellvitge, Anatomic Pathology, Barcelona, Spain; ⁴Hospital Universitario Arnau de Vilanova, Pathology, Lleida, Spain; ⁵Robert J. Tomsich Pathology and Laboratory Medicine Institute, Pathology, Cleveland, USA

10.1136/ijgc-2019-IGCS.12

Objectives Adult granulosa cell tumors (aGCTs) are rare ovarian tumors underpinned by the FOXL2 p.C134W mutation, with a 10–30% risk of relapse. We sought to determine the genetic alterations underpinning primary and recurrent aGCTs.

Abstract 11 Table 1

	TOTAL LATAM	ARGENTINA	BRAZIL	COLOMBIA	MEXICO	PANAMA	PERU
Total tested in tumor tissue N	376	105	101	74	44	22	30
BRCA ^M tissue N (%)	112 (29,78%)	34 (32,4%)	27 (26,7%)	17 (23%)	18 (40,9%)	3 (13,6%)	13 (43,3%)
gBRCA ^M N (%)	67 (59,82%)	24 (70,6%)	17 (63%)	5 (29,4%)	16 (88,9%)	1 (33,3%)	4 (30,8%)
sBRCA ^M N (%)	32 (28,57%)	7 (20,6%)	4 (14,8%)	12 (70,6%)	0 (0%)	2 (66,6%)	7 (53,8%)
Inconclusive	13 (11,6%)	3 (8,8%)	6 (22,2%)	0 (0%)	2 (11,1%)	0 (0%)	2 (15,4%)

Methods Thirty-five aGCTs were subjected to massively parallel sequencing targeting 468 cancer-related genes (7 primary aGCTs that did not recur >4 years, 9 primary and matched recurrent aGCTs, 10 recurrent aGCTs). These cases and additional 12 aGCTs (n=3, primary aGCTs that did not recur; n=9, recurrent aGCTs) were subjected to Sanger sequencing analysis of the *TERT* promoter.

Results All aGCTs included harbored the *FOXL2* p.C134W hotspot mutation. A significantly higher frequency of *TERT* promoter mutations was found in recurrent (64%) than in primary aGCTs (26%; $p=0.017$). Moreover, aGCT recurrences harbored a higher frequency of somatic *KMT2D* and *TP53* mutations (16%, each) than primary aGCTs with subsequent recurrences (11% and 0%) and primary aGCTs without subsequent recurrences (14% and 0%). We identified a higher frequency of *CDKN2A/B* homozygous deletions in recurrent (16%) than in primary aGCTs (6%), and other gene alterations restricted to recurrent aGCTs. Pathway analysis revealed that aGCTs are underpinned by genetic alterations affecting the cell cycle pathway. Clonal decomposition of matched primary and recurrent aGCTs showed that aGCTs display multiple clones at diagnosis and relapse.

Conclusions Our findings suggest that although *FOXL2* plays a crucial role in the tumorigenesis of aGCTs, recurrences might be associated with genetic alterations affecting *TERT*, cell cycle-related genes such as *TP53* and *CDKN2A/B*, and other cancer-related genes, including *KMT2D*, *TET2* and *EPHA5*.

IGCS19-0511

13 MUCINOUS OVARIAN CARCINOMA: THERAPEUTIC OPTIONS OLD AND NEW

¹K Gorringer*, ¹D Cheasley, ²M Wakefield, ¹I Campbell, ³Y Antill, ⁴C Scott, ¹G GAMuT Collaborators. ¹Peter MacCallum Cancer Centre, Research Division, Melbourne, Australia; ²Walter and Eliza Hall Institute, Bioinformatics, Melbourne, Australia; ³Cabrini Health, Oncology, Melbourne, Australia; ⁴Walter and Eliza Hall Institute, Stem Cells and Cancer Division, Melbourne, Australia

10.1136/ijgc-2019-IGCS.13

Objectives Mucinous ovarian carcinoma (MOC) is a rare ovarian cancer subtype that responds poorly to conventional chemotherapy. Recurrent and advanced disease have poor survival and there are no specific guidelines for their treatment. We used a large cohort of genomic and immunohistochemical data to evaluate the likelihood of success of possible therapeutic interventions.

Methods We used DNA sequencing data (n=185) and genome-wide copy number (n=199) from primary MOC to identify key genetic events, homologous recombination deficiency scores and mismatch repair deficiency. Immunohistochemistry data was obtained for CK7, CK20, PAX8, p16, CDX2, HER2 and ER (n=162–256) and tumour infiltrating lymphocytes were counted on H&E stained slides (n=40).

Results Therapies exploiting homologous recombination deficiency are unlikely to be effective in MOC, as only 1.5% had a homologous recombination deficiency score of more than 50. Mismatch repair deficiency was very rare (<1%). Most cases had low lymphocytes counts, corresponding to a moderate mutation load. Events that suggest an existing targeted therapy include: *ERBB2* amplification(26%), *ERBB3* mutation

(4%) and *BRAF* mutation(9%). Novel agents currently in clinical trials targeting genetic events such as *TP53* missense mutation(46%), *RNF43* mutation(11%), *PIK3CA* mutation(8%) and *KRAS/NRAS* mutations(66%).

Conclusions MOC is genetically diverse but with a number of potential targets. Importantly, the clinically observed lack of response to cisplatin is supported by a corresponding lack of a genomic signature, and MOC are unlikely to respond to PARP inhibitors. The role of immunotherapy is unclear. Testing novel therapeutic options in appropriate patient-derived models will be crucial and we are currently developing organoid cultures from this disease.

Plenary 3

IGCS19-0583

14 THE LONG-TERM ONCOLOGIC OUTCOMES OF MINIMALLY INVASIVE SURGERY(ROBOT-ASSISTED/LAPAROSCOPIC) VERSUS ABDOMINAL RADICAL HYSTERECTOMY FOR EARLY-STAGE CERVICAL CANCER PATIENTS TREATED BETWEEN 2000 AND 2017 AT THE OSLO UNIVERSITY HOSPITAL

¹MB Sert*, ¹A Dørum, ¹G Kristensen, ²B Davidson, ^{3,4}A Dahl. ¹Oslo University Hospital- The Norwegian Radium Hospital, Gynecologic Oncology, Oslo, Norway; ²Oslo University Hospital- The Norwegian Radium Hospital, Pathology, Oslo, Norway; ³Oslo University Hospital- The Norwegian Radium Hospital, National Resource Center for late effects after cancer treatment, Oslo, Norway; ⁴Institute of Clinical Medicine, University of Oslo, Oslo, Norway

10.1136/ijgc-2019-IGCS.14

Objectives To compare the long-term oncologic outcomes after minimally invasive surgery (robot assisted/laparoscopic radical hysterectomy) (MIS) versus abdominal radical hysterectomy (ARH) for early-stage cervical cancer (CC).

Methods This is a large single center retrospective study. From our institution's patient registry, we identified a total of 587 early-stage cervical cancer patients who underwent either MIS or ARH between 2000 and 2017. We excluded the following patients from the final analysis: (1) received neo-adjuvant treatment prior to surgery; (2) had histologic types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; (3) were double primary cancer cases; (4) had stages higher than stageIB1 (FIGO 2009). We included only patients who underwent radical hysterectomy for early-stage cervical cancer and radical parametrectomy for stump cancer patients in our study population.

Results In total, 230 and 357 patients were assigned to the MIS and ARH groups, retrospectively. There were no significant differences for any demographics including age, stage, histology. Five-year recurrence free survival was 88.6% (95% CI, 83.4%- 92.3%) and 93.5% (95% CI, 90.4%- 95.7%), ($p=0.04$) respectively in the MIS and ARH group, and the five-year cancer specific survival was 95.4% (95% CI, 90.9%- 97.7%) and 97.4% (95% CI, 95.1%- 98.7%), ($p=0.12$) in the MIS and ARH group, respectively. MIS group have more peritoneal-combined relapses comparing ARH ($p=0.02$). The relapse rate tended to be highest for squamous cell carcinoma in MIS group ($p=0.09$). Disease free survival and cancer specific survival were worse in the MIS group p -value= 0.04 and 0.12 respectively.